Stock 6575 SYNEURX INTERNATIONAL (TAIWAN) CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News SyneuRx International (Taiwan) Corp.

Equities

6575

TW0006575004

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2023-01-05 pm EST 		5-day change 1st Jan Change
17.2 TWD -.--% Intraday chart for SyneuRx International (Taiwan) Corp. -.--% -.--%
Apr. 29 SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
SyneuRx International Corp.(TPEX:6575) dropped from S&P Global BMI Index
CI
SyneuRx International Corp. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
BU
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir®
CI
SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
BU
SyneuRx™ International Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir®
CI
SyneuRx International Corp. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants
CI
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing
CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Half Year Ended June 30, 2019
CI
Syneurx International Taiwan Corp. Reports Earnings Results for the Full Year Ended December 31, 2018
CI
SyneuRx International Corp.(GTSM:6575) added to S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6575 Stock
  4. News SyneuRx International (Taiwan) Corp.